HuGE Literature Finder
Records 1-6
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Pharmacogenomics 2017 Oct . Sortica Vinicius A, Lindenau Juliana D, Cunha Maristela G, O Ohnishi Maria Deise, R Ventura Ana Maria, Ribeiro-Dos-Santos Ândrea Kc, Santos Sidney Eb, Guimarães Luciano Sp, Hutz Mara |
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.
Pharmacogenomics 2017 Jun . Vos Karin, Sciuto Carlotta Lo, Piedade Rita, Ashton Michael, Björkman Anders, Ngasala Billy, Mårtensson Andreas, Gil José Ped |
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.
Malaria journal 2017 07 16 (1): 267. Mutagonda Ritah F, Kamuhabwa Appolinary A R, Minzi Omary M S, Massawe Siriel N, Asghar Muhammad, Homann Manijeh V, Färnert Anna, Aklillu Ele |
The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.
Malaria journal 2017 09 16 (1): 383. Kiaco Kinanga, Rodrigues António Sebastião, do Rosário Virgílio, Gil José Pedro, Lopes Dino |
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
The pharmacogenomics journal 2015 May . Maganda B A, Minzi O M S, Ngaimisi E, Kamuhabwa A A R, Aklillu |
MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Clinical pharmacology and therapeutics 2006 Oct 80 (4): 367-74. Aarnoudse Albert L H J, van Schaik Ron H N, Dieleman Jeanne, Molokhia Mariam, van Riemsdijk Melanie M, Ligthelm Robert J, Overbosch David, van der Heiden Ilse P, Stricker Bruno H |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: